Skip to main content
Quest Diagnostics

Outcome of Atypical Urothelial Cells (AUC) in Patients Without Prior History of Urothelial Carcinoma

Outcome of Atypical Urothelial Cells (AUC) in Patients Without Prior History of Urothelial Carcinoma

Authors: Van Tassel E, Howell J, Walls K, Crabtree W

Citation: J Am Soc Cytopathol. 2025 Jun 16:S2213-2945(25)00077-8. doi: 10.1016/j.jasc.2025.06.001. Online ahead of print.

Specialties: Oncology

Disclaimer: One or more of the authors of this publication were employed at the time by AmeriPath Diagnostics, a subsidiary of Quest Diagnostics.

Related content

Audio Podcast
Optimize Oncology Care with Clinical Pathways
Audio Podcast
Molecular Expression Through the Eyes of the Pathologist and Oncologist
Publication
Malignant Pericardial Effusion from Cervical Squamous Cell Carcinoma: A Case Study
Publication
Case Report: Complete Response of Recurrent Locally Advanced Basal Cell Carcinoma Following Addition of Vismodegib to Neoadjuvant Cemiplimab Therapy

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.